Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Weighted Avg Shares (Diluted) · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares (diluted) grows 18.6% year over year

Q4 FY2025 weighted avg shares (diluted) of 92.6M shares rose 18.6% year over year. Over 3 fiscal years it compounded at +75.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
92.6M— QoQ
Last fiscal yearDec 2025
89.03M+17.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.6%——
1 year+17.9%——
3-year CAGR+75.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
89.03M CNY
Year-over-year change
+17.9%
4-year CAGR
+53.8%

Weighted Avg Shares (Diluted) vs competitors

How AAPG compares with its peers on the latest reported figures

  • AAPG's FY2025 weighted avg shares (diluted) of 89.03M shares is the 6th highest of the 11 companies compared; the peer median is 92.73M shares.
  • Its year-over-year change of +17.9% is the 8th highest of 10, against a peer median of +31.0%.
  • Over three fiscal years its annual growth of +75.5% compares with a peer median of +18.9%.
AAPG Competitors Peer median
Weighted Avg Shares (Diluted) for AAPG and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026353.26M +9.5%+16.4%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
VSTMVerastem, Inc.LTM Mar 202682.44M +107.0%+62.5%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding AAPG) 92.73M+31.0%+18.9%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.